Inventiva S.A.

IVA | NASDAQ

Price Alert Chart Builder DCF Calculator

€3.78

+€0.03 (+0.80%)

At close: Sep 18, 2026, 4:00 PM ET

€3.69

-€0.09 (-2.28%)

Pre-market: Sep 21, 2026, 8:22 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.80%

(1D)

Rating

Updated: Sep 12, 2026

14.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap €196.49M

1D Range

3.66 3.82

52W Range

3.35 7.98

Valuation (TTM)

PE -1.99

PB -6.77

EV/EBITDA -0.64

Valuation (NTM)

Forward PE N/A

Forward PEG -0.44

Price Target €14

Cash Flow

FCF Yield -55.2%

SBC Adj. FCF Yield -59.2%

SBC Impact -7.4%

Margins

Gross Margin 35.1%

Operating Margin -2921.1%

FCF Margin -2418.1%

Growth (CAGR)

Revenue 3Y | 5Y -21.3% | -12.3%

Dil EPS 3Y | 5Y -23.3% | -15.6%

FCF 3Y | 5Y -44.2% | -42.6%

Returns

ROA -141.9%

ROE 1870.4%

ROIC -66.2%

Financial Health

Net Cash

€44.23M

Current Ratio 3.16

Interest Coverage -4.06

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets s...

Sector Healthcare

Industry Biotechnology

Employees 73

IPO Date Jul 9, 2020

Website www.inventivapharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Sep 25, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$14

Upside

+270.37%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞